硫酸脱氢表雄酮与基线皮质醇在评估肾上腺功能不全中的表现
单中心回顾性队列研究纳入2005至2023年间接受促肾上腺皮质激素刺激试验且试验前3个月内测过硫酸脱氢表雄酮的1135例成人,评估硫酸脱氢表雄酮与基线皮质醇对肾上腺功能不全的诊断表现。肾上腺功能不全患病率为17.2%,两者曲线下面积均为0.81;近期使用糖皮质激素会降低硫酸脱氢表雄酮的诊断表现。作者认为联合检测基线皮质醇与硫酸脱氢表雄酮或可使许多患者免于进一步动态试验。
要点
- 1135例中195例(17.2%)存在肾上腺功能不全。
- 硫酸脱氢表雄酮与基线皮质醇诊断肾上腺功能不全的曲线下面积均为0.81。
- 基线皮质醇≥10 mcg/dL者仅1.2%存在肾上腺功能不全。
核心结论
- 硫酸脱氢表雄酮在评估肾上腺功能不全方面具有良好的诊断表现。
- 同时测定基线皮质醇和硫酸脱氢表雄酮浓度或可使许多患者免于进一步动态试验。
研究设计与样本
- 单中心回顾性队列研究,纳入2005至2023年间接受促肾上腺皮质激素刺激试验且试验前3个月内测过硫酸脱氢表雄酮的成人患者,共1135例。
主要发现
- 1135例患者中195例(17.2%)存在肾上腺功能不全。
- 基线皮质醇与硫酸脱氢表雄酮均独立具有良好的诊断表现,曲线下面积分别为0.81(95%CI 0.77-0.84)和0.81(95%CI 0.78-0.85)。
- 促肾上腺皮质激素刺激试验的执行时间对基线皮质醇的诊断准确性无显著影响,而近期使用糖皮质激素降低了硫酸脱氢表雄酮的诊断表现(曲线下面积0.72 vs 0.83)。
- 基线皮质醇≥10 mcg/dL的患者中仅1.2%经促肾上腺皮质激素刺激试验判定存在肾上腺功能不全。
- 基线皮质醇在5至9.9 mcg/dL之间且硫酸脱氢表雄酮≥60 mcg/dL的患者中仅1.3%存在肾上腺功能不全;而基线皮质醇<5 mcg/dL且硫酸脱氢表雄酮<25 mcg/dL的患者中多数(72.2%)存在肾上腺功能不全。
关键数值与推荐
- 基线皮质醇≥10 mcg/dL者肾上腺功能不全比例为1.2%。
- 基线皮质醇5至9.9 mcg/dL且硫酸脱氢表雄酮≥60 mcg/dL者肾上腺功能不全比例为1.3%。
- 基线皮质醇<5 mcg/dL且硫酸脱氢表雄酮<25 mcg/dL者肾上腺功能不全比例为72.2%。
临床怎么用
- 作者认为同时测定基线皮质醇和硫酸脱氢表雄酮浓度或可使许多患者免于进一步动态试验。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Diagnosing adrenal insufficiency (AI) often requires complex testing, which can be time-consuming and expensive. Dehydroepiandrosterone sulfate (DHEAS) is a promising marker of hypothalamic-pituitary-adrenal axis function; however, its diagnostic performance has not yet been evaluated in a large-scale study. OBJECTIVE: Evaluate the performance of DHEAS and baseline cortisol in assessing AI. DESIGN: Single-center retrospective cohort study. SETTING: Referral center. PATIENTS: Adults who underwent cosyntropin stimulation testing (CST) between 2005 and 2023 and had DHEAS measured within 3 months prior to CST. MAIN OUTCOME MEASURES: Area under receiver operating characteristic curve (AUROC) for DHEAS and baseline cortisol. Prevalence of AI based on various DHEAS and baseline cortisol concentrations. RESULTS: Among 1135 patients, 195 (17.2%) had AI. Both baseline cortisol and DHEAS independently had good diagnostic performance with AUROC 0.81 [95% confidence interval (CI) 0.77-0.84 and 0.81 (95% CI 0.78-0.85)], respectively. Time of CST performance had no significant effect on diagnostic accuracy of baseline cortisol while recent glucocorticoid use decreased diagnostic performance of DHEAS (AUROC 0.72 vs 0.83). Only 1.2% of patients with baseline cortisol ≥10 mcg/dL had AI based on CST. Among patients with baseline cortisol between 5 and 9.9 mcg/dL, only 1.3% had AI if DHEAS was ≥60 mcg/dL. Conversely, the majority (72.2%) of patients with both baseline cortisol <5 mcg/dL and DHEAS <25 mcg/dL were found to have AI. CONCLUSION: DHEAS has good diagnostic performance in assessing AI. Measuring both baseline cortisol and DHEAS concentrations may eliminate the need for further dynamic testing in many patients.
引用
- Han AJ, Suresh M, Gruber LM, et al. Performance of Dehydroepiandrosterone Sulfate and Baseline Cortisol in Assessing Adrenal Insufficiency. J Clin Endocrinol Metab. 2025. PMID: 39657727. doi:10.1210/clinem/dgae855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。